Molecular 'switch' in fat cells fuels cancer growth

White fat cells

A type of fat, known as “white fat,” can fuel the growth of cancers in humans, especially when it’s found in excess. Previously, how this process occurred remain a mystery. Now, researchers from the University of Texas have discovered a switch that may control this obesity-induced cancer growth, giving hope for the development of new treatments.

Mikhail Kolonin, the senior author of the study, led a team that published their work in the journal Nature Communications.

“Some tumors rely on fat to grow aggressively,” said Kolonin. “We’ve discovered a molecular network without which fat no longer promotes tumor growth.”

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

The molecular switch they identified goes under the name of CXCL1--a chemokine that signals to cells to regulate their movement. When they blocked the expression of CXCL1 in a mouse model of obesity-induced prostate cancer, they were able to slow the cancer growth. They used prostate cancer as a model since it’s propagated and driven by the accumulation of white fat tissue.

Importantly, when they applied their findings to humans, they found CXCL1 elevated in the fat tissue of patients with prostate cancer and obesity, as compared to patient controls with prostate cancer and no obesity.

Deepening their findings, they overexpressed CXCL1 in a genetic mouse model and found that the switch signals to cells within the fat, called adipose stromal cells (ASCs), to move towards tumor tissue providing nutrients and support to the cancer.

With the potential for treating obese patients with cancer blocking the switch may hold therapeutic value for these patients. “We’re exploring multiple ASC-targeting strategies,” Kolonin said in a statement. “Blockade of CXCL1 function to recruit ASC to tumors could be developed to intervene in cancer progression.”

- here’s the release
- here’s the Nature Communications abstract

Related Articles: 
UCLA scientists show new tumor-suppressor gene can reduce cervical cancer growth
Myeloid-derived suppressor cells play role in tumor growth
Ohio scientists block chromatin-modifying enzyme, suppressing glioblastoma growth

 

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.